| Compound stress model | Cognitive dysfunction and mechanism | Potential therapeutic target | Reference |
| Stress+AD | Stress aggravates cognitive impairments and neurodegeneration (1) Inhibition of AQP4 (2) Aβ and p-Tau accumulation↑ (3) Aβ clearance rate↓ (4) Increased Aβ production (5) ROS↑ (6) Metabolic disorders | Glucocorticoid inhibitor HPA axis inhibitor Autophagy activator AQP4 activator Antioxidant drugs | [5, 105, 109, 110, 112, 114, 115, 117] |
| Stress+Stroke | Brain lesions, cognitive deficits, and neurodegeneration↑ (1) Prevents angiogenesis (2) Overactivation of ERS and inhibition of astrocytes, microglia (3) ROS, neuroinflammation, and glutamate↑ (4) Glucose utilization, TJ-related protein degradation↑ | Vasoactive drugs Anti-inflammatory drug Antioxidant drugs | [122, 123, 125–128, 131, 132, 141] |
| Stress+TBI | Cognitive impairment, lesion volume↑ (1) MCP-1, MIP-1α, TNF-α, and IL-6↑ (2) BDNF generation↓ (3) Activates ER stress-mediated neurodegeneration (4) Disorders of HPA axis | Anti-inflammatory drug BDNF ERS inhibitor, such as salubrinal Antioxidant drugs | [9, 142, 144–146, 165, 172, 173] |
| Stress+Epilepsy | Increases susceptibility to epilepsy Hippocampal ERS Oxidative stress↑ | ERS inhibitor, such as TUDCA | [67, 79, 165–167, 174] |
|
|